Investing.com-- Shares of Telix Pharmaceuticals (ASX:TLX) jumped on Tuesday after the company reported positive results from a late-stage trial of its experimental prostate cancer therapy.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 –– Reduced secured and convertible debt by 90% from ...

John Tesh says he has outlived a terminal cancer prognosis by nearly eight years while continuing treatment for metastatic ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with cancer more than a decade ago - but he still lives with the disease.

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

The former 'Entertainment Tonight' co-host revealed in 2015 that he had been diagnosed with a rare form of prostate cancer ...

John Tesh reveals he was given 18 months to live after a rare metastatic prostate cancer diagnosis. Here are the details.

The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.